Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 360-365

  Seo, Hee Yeon ^a   Lee, Hyun Joo ^b   Woo, Ok Hee ^b   Park, Kyong Hwa ^a   Woo, Sang Uk ^b   Yang, Dae Sik ^b   Kim, Ae Ree ^b   Lee, Jae Bok ^b   Lee, Eun Sook ^b   Kim, Yeul Hong ^a   Kim, Jun Suk ^a   Seo, Jae Hong ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Anthracyclines; Chemotherapy; Metastatic breast cancer; Taxanes; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DRUG DERIVATIVE; TAXANE; TAXOID; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; CLINICAL TRIAL; DOSE RESPONSE; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 79957519270     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9357-y     Document Type: Article

References (17)

1. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J et al (2007) National cancer incidence for the year 2002 in Korea. Cancer Res Treat 39:139-149
2. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ et al (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174-1181
3. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A et al (1989) Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16:9-14 (Pubitemid 19137821)
4. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252 (Pubitemid 23199126)
5. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA et al (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341 (Pubitemid 24056407)
6. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L et al (1995) Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18:392-396
7. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M et al (1996) Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 39:285-291 (Pubitemid 26278943)
8. Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ et al (1994) A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993 (Pubitemid 24331101)
9. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B et al (1999) Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397-402 (Pubitemid 29236416)
10. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J et al (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730
11. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D et al (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423-426 (Pubitemid 24159646)
12. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C (1996) Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel-a phase II study. Cancer Chemother Pharmacol 39:150-156 (Pubitemid 26400674)
13. Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C, Coombes RC (2000) Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 36:177-182 (Pubitemid 30102193)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
15. Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T et al (2005) Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 35:310-315 (Pubitemid 41444278)
16. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267-2272 (Pubitemid 33029069)
17. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C et al (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 15:1395-1400 (Pubitemid 27167371)